InsiderSignal.AI

InsiderSignal.ai

KURA - Kura Oncology, Inc.

Insider Purchase by Wilson Troy Edward (Pres, CEO)

1 Year
After Trade
Before Trade

Loading data...

Trade Summary

6 months ago, Wilson Troy Edward, serving as Pres, CEO at Kura Oncology, Inc. (KURA), purchased 50,000 shares at $6.06 per share, for a total transaction value of $303,201.00. Following this transaction, Wilson Troy Edward now holds 630,162 shares of KURA.

This purchase represents a 9.00% increase in Wilson Troy Edward's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, August 12, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, August 14, 2025, 2 days after the trade was made.

Kura Oncology, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Wilson Troy Edward

Pres, CEO

Troy E. Wilson, Ph.D., J.D. is a President, CEO, and Chairman of Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company focused on precision oncology medicines.[[1]](https://kuraoncology.com/leadership/troy-wilson/)[[3]](https://kuraoncology.com/about-us/) One of Kura's co-founders, he has held these roles since the company's inception in August 2014.[[1]](https://kuraoncology.com/leadership/troy-wilson/)[[2]](https://www.biotech2050.com/episodes/the-promise-of-precision-oncology-troy-wilson-president-amp-ceo-kura-oncology)[[3]](https://kuraoncology.com/about-us/) Dr. Wilson is a serial entrepreneur with over 25 years in biopharma. He previously co-founded and served as President and CEO of Araxes Pharma LLC and Wellspring Biosciences, Inc., pioneering KRAS oncoprotein inhibitors; Intellikine, acquired by Takeda in 2011; and was Chief Business Officer at Ambrx, acquired by Johnson & Johnson in 2024. He also co-founded Avidity Biosciences (NASDAQ: RNA), serving as its Chairman.[[1]](https://kuraoncology.com/leadership/troy-wilson/)[[2]](https://www.biotech2050.com/episodes/the-promise-of-precision-oncology-troy-wilson-president-amp-ceo-kura-oncology)[[3]](https://kuraoncology.com/about-us/)[[6]](https://www.biospace.com/press-releases/cartography-announces-appointment-of-troy-wilson-ph-d-j-d-to-its-board-of-directors) Currently, he serves on the boards of Puma Biotechnology, Cartography Biosciences, and Avidity Biosciences.[[1]](https://kuraoncology.com/leadership/troy-wilson/)[[4]](https://fintool.com/app/research/companies/PBYI/people/troy-wilson)[[6]](https://www.biospace.com/press-releases/cartography-announces-appointment-of-troy-wilson-ph-d-j-d-to-its-board-of-directors) Dr. Wilson holds a J.D. from New York University, a Ph.D. in bioorganic chemistry, and a B.A. in biophysics from UC Berkeley.[[1]](https://kuraoncology.com/leadership/troy-wilson/)[[2]](https://www.biotech2050.com/episodes/the-promise-of-precision-oncology-troy-wilson-president-amp-ceo-kura-oncology)[[4]](https://fintool.com/app/research/companies/PBYI/people/troy-wilson)

View full insider profile →

Trade Price

$6.06

Quantity

50,000

Total Value

$303,201.00

Shares Owned

630,162

Trade Date

Tuesday, August 12, 2025

194 days ago

SEC Filing Date

Thursday, August 14, 2025

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Kura Oncology, Inc.

Company Overview

No company information available
View news mentioning KURA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/128030

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime